6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00252850 (ClinicalTrials.gov) | June 2005 | 11/11/2005 | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease | A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease | Parkinson's Disease | Genetic: CERE-120: AAV2-NTN | Sangamo Therapeutics | Ceregene | Completed | 35 Years | 75 Years | All | 12 | Phase 1 | United States |